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Abstract
Background: Accumulation of galactosphingolipids is a general characteristic of Fabry disease, a lysosomal storage
disorder caused by the deficient activity of α-galactosidase A encoded by the GLA gene. Although many polymorphic
GLA haplotypes have been described, it is still unclear whether some of these variants are causative of disease
symptoms. We report the study of an inheritance of a complex intronic haplotype (CIH) (c.-10C > T, c.369 + 990C > A,
c.370-81_370-77delCAGCC, c.640-16A > G, c.1000-22C > T) within the GLA gene associated with Fabry-like symptoms
and galactosphingolipid accumulation.
We analysed α-Gal A activity in plasma, leukocytes and skin fibroblasts in patients, and measured accumulation of
galactosphingolipids by enzymatic methods and immunofluorescence techniques. Additionally, we evaluated GLA
expression using quantitative PCR, EMSA, and cDNA cloning.
Results: CIH carriers had an altered GLA expression pattern, although most of the carriers had high residual enzyme
activity in plasma, leukocytes and in skin fibroblasts. Nonetheless, CIH carriers had significant galactosphingolipid
accumulation in fibroblasts in comparison with controls, and also glycolipid deposits in renal tubules and glomeruli.
EMSA assays indicated that the c.-10C > T variant in the promoter affected a nuclear protein binding site.
Conclusions: Thus, inheritance of the CIH caused an mRNA deregulation altering the GLA expression pattern,
producing a tissue glycolipid storage.
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Background
α-galactosidase A (α-Gal A, EC3.2.1.22) is a lysosomal en-
zyme that hydrolyses the terminal α-galactosyl moieties
from glycolipids. α-Gal A is encoded by the GLA gene and
mutations in this gene causes deficiency or absence of the
enzyme, resulting in Fabry disease (FD) (OMIM 301500),
an X-linked inherited lysosomal storage disorder. This dis-
ease leads to accumulation of globotriaosylcermide (Gb3),
globotriaosylsphingosine (lyso-Gb3), galabiosylceramide
(Ga2) and neutral glycosphingolipids in lysosomes of
several tissues, mainly in the endothelium of the
vascular tree [1]. Depending on the GLA mutation
and when manifestations initially occur, FD is classi-
fied as late-onset or classic phenotype. In males with
no, or reduced, α-Gal A enzyme activity, clinical
manifestations of the classic form include acropar-
esthesias, angiokeratomas, hypohidrosis, corneal and
lenticular opacities, cardiac dysfunction and brain and
renal involvement with proteinuria [2]. Heterozygous
females can either be asymptomatic, due to random
X-chromosomal inactivation [3], or can develop the
classic phenotype [1]. Because of the nonspecific
nature of its clinical manifestations, FD often remains
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undiagnosed in concordance with the prevalence calcu-
lated in some studies [4, 5]; however, early treatment is
essential to avoid significant disease progression [6, 7].
Over 700 GLA mutations, including missense and non-
sense mutations, rearrangements, and splicing defects, have
been identified as causing FD [8] (http://www.hgmd.cf.
ac.uk/ac/index.php). GLA [ENSG:00000102393] has seven
splice variants (http://www.ensembl.org) and aberrant spli-
cing accounts for ~5 % of mutations in FD (reported to the
Human Gene Mutation Database; http://www.hgmd.cf.
ac.uk), but information on pre-mRNA splicing is only avail-
able for a limited number of patients. Exonic mutations
may also alter splicing, but are not easily recognized [9].
Many polymorphic GLA variants have been described, but
it is unclear if haplotypes formed by combinations of these
variants correlate with FD. A complex intronic haplotype
(CIH) within the GLA gene (c.-10C >T, c.640-16A >G,
c.1000-22C >T) is associated with early occurrence of
small-fibre neuropathy [10]. A screening study found
a second CIH (c.-10C > T, c.370-81_370-77delCAGCC,
c.640-16A > G, c.1000-22C > T) in 8.9 % of subjects
with FD symptoms [11]; associated with hypertrophic
heart disease [12] and, additionally, an analysis of the
male control population of a suspected FD female
index case permitted the identification of seven differ-
ent GLA haplotypes [13]. Finally, a recent study de-
scribed a large family with four male/female carriers
of a CIH who developed a classical phenotype with a
mild renal and neurological involvement [14]. Some
of these intronic variants have been reported as poly-
morphic variants in general population [15–17].
We performed a functional characterization of a
large family with a CIH in the GLA gene and investi-
gated the molecular pathological mechanisms associ-
ated with different FD-related clinical manifestations.
We demonstrate that the inheritance of this CIH
causes GLA gene deregulation and glycolipid storage.
Methods
Patients
We studied a family with different FD-related clinical
manifestations. This family carried a CIH (c.-10C > T
[rs2071225], c.369 + 990C >A [rs1023431], c.370-81_370-
77delCAGCC [rs5903184], c.640-16A >G [rs2071397],
c.1000-22C > T [rs2071228]). The family consisted of 15
individuals (6 heterozygous and 4 hemizygous for CIH)
aged between 7 and 72 years. Written informed consent
was obtained from all patients including those from
the parents on the behalf of the minors involved in
our study. The study was approved by the Ethics
Committee of Aragon (CEICA) and was conducted in
accordance with the Declaration of Helsinki of 1975,
as revised in 2008.
Reagents
The recombinant enzyme used was agalsidase alfa
(REPLAGAL) from Shire pharmaceuticals. As a source
of enzyme, we used the residual amounts of the
reconstituted recombinant enzyme prepared for the
treatment of FD patients. TNFα was purchased from
Miltenyi Biotec. The pharmacological chaperone, DGJ (1-
deoxygalactonojirimycin hydrochloride), was purchased
from Santa Cruz Biotechnology. The anti-human CD77
(Gb3) primary rat monoclonal antibody used for immuno-
fluorescence analysis was purchased from Biorbyt; the
anti-human CD17 (lactosylceramide) mouse monoclonal
antibody was from Santa Cruz Biotechnology and the
anti-human LAMP1 rabbit monoclonal antibody was
from Sigma-Aldrich. Secondary conjugated antibodies
were Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor
488 goat anti-rat IgG and Alexa Fluor 488 goat anti-
mouse IgG, all from Life Technologies.
α-Gal A activity assay
The activity of α-Gal A was determined in plasma,
lysed leukocytes and lysed fibroblasts (in triplicate)
with a fluorometric assay using the artificial substrate
4-methylumbelliferyl (MU)-α-D-galactopyranoside (Sigma-
Aldrich); for the assay of cell extracts, N-acetyl-D-
galactosamine (Sigma-Aldrich) was used to inhibit
α-galactosidase B (α-Gal B) [18]. The fluorescence of re-
leased 4-MU was measured in two replicates at an excita-
tion wavelength of 366 nm and emission wavelength of
445 nm in a fluorometer (Perkin Elmer LS-45).
Fibroblast culture
Human skin fibroblasts were cultured in 175 cm2 flasks
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with GlutaMAX, 10 % heat-inactivated fetal
bovine serum (FBS), 0.5 % β-amphotericin (250 μg/mL)
and the antibiotics streptomycin (100 mg/L) and penicil-
lin (100 U/L). Cells were maintained at 37 °C in a 5 %
CO2 atmosphere and the medium was replenished every
72 h. After reaching confluence, cells were kept
quiescent for 5 days, washed with PBS and harvested
by trypsin (0.05 % trypsin/EDTA for 5 min). All
reagents were provided by Gibco-Invitrogen. Cell sus-
pensions were pelleted by centrifugation at 290×g for
5 min. After removing the supernatant, cells were
washed twice with PBS and stored at −20 °C for
further analysis.
Cell culture model of lysosomal storage dysregulation
Fibroblasts were cultured in DMEM with 1 % inactivated
FBS in 6-well culture plates (160, 000 cells/ 9.5 cm2).
Twenty-four hours before experimentation, cells were
activated with 0.1 nM TNFα for 16 h. After activation, the
medium was renewed and, where indicated, cells were
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additionally incubated with DGJ (500 μM) for 24 h to
inhibit endogenous α-galactosidase activity [19] or with
agalsidase alfa, by adding 3 ml of the enzyme solution
(1.32 μg of enzyme per ml; final activity 3.8 μmol MU
mg−1.h−1) [20], to analyze galactolipid degradation as
an endogenous control. Cell cultures were incubated
for different periods of time (0, 16 and 24 h) and at
least two 9.5 cm2 wells were analyzed for each treat-
ment combination.
Quantification of galactosphingolipids
Determination of galactosphingolipids using galactose
oxidase was carried out in cell pellets from lysed leuko-
cytes and fibroblasts previously suspended in 1 % sodium
taurocholate (Sigma-Aldrich) and disrupted by combin-
ation of ultrasound short pulse (VibraCell) and timing-out
on ice. Samples were kept on ice during the procedure.
The lysate was centrifuged at 112×g for 10 min at 4 °C to
eliminate cell debris and 50 μl of supernatant was used for
quantification. Measurement of galactosphingolipids was
performed using the Amplex Red Galactose/Galactose
Oxidase Assay Kit (Invitrogen).
Immunofluorescence analysis
Immunocytochemistry was performed to examine the
distribution of CD77, CD17 and LAMP1. Fibroblasts
grown on coverslips were fixed with 4 % paraformalde-
hyde for CD77/LAMP1 analysis and with methanol for
CD17/LAMP1 localization, permeabilized with 0.1 %
saponin and blocked with 0.1 % saponin 5 % BSA diluted
in PBS. Cells were incubated with primary antibodies
(CD77 diluted to 50 μg/ml, CD17 diluted to 2 μg/ml and
LAMP1 diluted to 0.2 μg/ml) overnight at 4 °C and then
conjugated secondary antibodies diluted to 0.1 μg/ml
were added and were incubated for 20 min at 25 °C.
Coverslips were mounted on slides and covered with
5 μl of DAPI-Mowiol medium (Life Technologies/
Calbiochem). All samples were examined with an Olym-
pus FluoView FV10i confocal microscope under identical
conditions. We used 405 nm, 473 nm and 635 nm
excitation lasers, which were switched on separately to re-
duce crosstalk of the two fluorochromes. A threshold was
applied to the images to exclude ∼ 99 % of the signal found
in control images. Pixel and cell surface fluorescence
quantification was done using FV10-ASW 3.1 software
from Olympus.
Molecular GLA analysis
Genomic DNA was isolated from whole blood by stand-
ard procedures. The entire GLA gene (g.101409127-
g.101397726) including promoter, exons and introns,
was amplified by PCR using the primers described in
Additional file 1. Amplicons were purified and se-
quenced in an automated DNA sequencer (3500XL
genetic analyser, Applied Byosistems). Sequences were
compared with the genomic GLA reference sequence
[ENSG:00000102393].
Multiplex Ligand Probe Amplification (MLPA) GLA analysis
Patients F1.1, F1.4 and F1.10 were analysed by
MLPA technique in order to find any pathological
rearrangement in GLA gene. The details of the
MLPA probe target regions and test methodology are
described by MRC Holland (http://www.mlpa.com).
SALSA MLPA P159 GLA probemix, version A2
(MRC Holland, Netherlands) was used and data were
normalized using 3 healthy controls matched by age
and sex.
RNA isolation, cDNA synthesis, small RNA cloning, and
quantitative real-time PCR
Total RNA was isolated from patients and control
peripheral blood samples using the PAXgene Blood
RNA Kit (PreAnalytiX). RNA integrity was assessed
by agarose gel electrophoresis and concentration was
determined in a NanoVue 4282 V1.7.3 Spectropho-
tometer (GE Healthcare). Total RNA (1 μg) was
reverse transcribed in triplicate 20 μL reactions using
the SuperScript II reverse transcriptase Kit (200 units)
and Oligo(dT)12–18 (500 μg/mL) (Invitrogen). The RT-
PCR profile was: 10 min at 42 °C, 45 min at 60 °C,
and 5 min at 95 °C.
To identify splicing variants, the entire GLA mRNA
was amplified by PCR using 1 μL cDNA and the
primers described in Additional file 1. The amplifica-
tion conditions were: 2 min at 94 °C followed by
40 cycles of 20 s at 94 °C, 30 s at 57 °C, and 30 s at
72 °C, and a final extension of 72 °C for 4 min.
Amplicons were diluted and nested PCR was per-
formed to amplify the GLA mRNA in two parts.
Both amplicons were purified with ExoSap-IT (GE
Healthcare) and sequenced.
A fragment of the 3′ region of intron 6 (g.101398149-
g.101398099) was amplified from cDNA of CIH carriers
by nested PCR using miScript PCR system and miScript
Primer Assays (Qiagen) trying to identify small RNA
fragments. The product was cloned into the pGEM-T
Easy Vector (Promega) and purified with the PureLink
Quick Plasmid Miniprep Kit (Invitrogen). Inserts were
amplified by PCR with T7 and SP6 universal primers,
and products were sequenced in forward and reverse
directions.
Quantification of GLA mRNA was performed in
triplicate samples from each patient using a quantita-
tive real-time PCR (qPCR) method based on TaqMan
technology (Applied Biosystems). Probe and primers
for wild-type GLA (ENST00000218516) and GLA-M
(cloned fragment) are listed in Additional file 1. qPCR
Gervas-Arruga et al. BMC Genetics  (2015) 16:109 Page 3 of 13
was performed with the ABI Prism 7000 Sequence
Detector (PE Applied Biosystems) using 20 ng of
cDNA in a reaction mixture containing 10 μl Univer-
sal Master Mix without amperase, 300 nmol of each
primer and 200 nmol of probe (Additional file 1).
Conditions for qPCR were: 95 °C for 10 min followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
We used efficiency-corrected gene expression mea-
surements [21].
Electrophoretic mobility shift assay (EMSA)
IRDye680-labelled double-stranded oligonucleotides with
the sequence GCTGTCCGGT[C/T]ACCGTGACAA were
purchased from LICOR Biosciences (Lincoln, NE,
USA). The preparation of nuclear extracts and the electro-
phoresis procedures have been described previously [22].
EMSA results were analysed and quantified using the
Odyssey Infrared Imaging System (LICOR Biosciences).
For competition assays, an excess of unlabelled T-allele
oligonucleotide was added to the mix prior to the addition
of the labelled oligonucleotides. The inverse of band in-
tensity was plotted against the excess of unlabelled oligo-
nucleotide and the slope of the resulting straight line
indicated the affinity of each allele for the proteins in the
nuclear extract.
Splice-site score (SSS)
Splice mutations were analysed using the SSPNN pro-
gram (http://www.fruitfly.org/seq_tools/splice.html) and
a splice-site score (SSS) was obtained.
Statistical analysis
Statistical analysis was carried out using the SPSS
software package (IBM). Normality of the distribution
of variables was analysed by the Kolmogorov-Smirnov
test, and mean comparison by the parametric t-test
and one way ANOVA. Differences with p ≤ 0.05 were
considered statistically significant.
Results
Patients
The family pedigree is shown in Fig. 1. The index case
(F1.1) was a 43-year-old female, with clinical records of
acroparesthesias from adolescence, hypohidrosis, and
reiterated episodes of abdominal pain with alternating
phases of diarrhoea with constipation. At 40 years of age
was referring several episodes of pain chest that requiring
emergency care. At 41 years of age she was hospitalized
by a new episode of chest pain and was diagnosed with
anteroseptal myocardial infarction, requiring the implant-
ation of three stents. The evaluation of hearth function by
MRI showed residual fibrous scar by myocardial infarction
in the territory of the anterior and apex segments. LV
slightly dilated with decreased LVEF (48.4 %) and
generalized hypokinesia. Valvular function with MI
moderate to severe and moderate AI. The cardiologic
diagnosis suspicion was valvular and ischemic hearth
variant secondary to Fabry disease. Complete haemato-
logical, neurological, and ophthalmological examinations
were performed, and renal function was measured and
determined to be normal. It discard associate factors of
hypercoagulability status. Peripheral nervous conduction
was evaluated by quantitative sensory test (QST) [23],
which revealed abnormalities in the small fiber conduction
compared with normal population. Physical examination
indicated that the patient had absence of hemangiokerato-
mas, nodes or visceral enlargement, and no cardiovascular
risks such as high plasmatic cholesterol, low c-HDL levels
Fig. 1 Pedigree of the family and complex intronic haplotype (c.-10C > T, c.369 + 990C > A, c.370-81_370-77delCAGCC, c.640-16A > G, c.1000-22C > T)
carriers. Index case is indicated with an arrow
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or hypertension. Genetic analysis revealed a CIH in the
GLA gene: IVSO-10C > T (c.-10C > T) within the pro-
moter region, intron 2 IVS2 + 990C >A (c.369 + 990 C >
A); IVS2-76_80del 5 (c.370-77_81 del CAGCC), intron 4
IVS4-16A >G (c.640-16A >G) and intron 6 IVS6-22C > T
(c.1000-22C > T). The same haplotype was identified in
the patient’s mother (F1.8) and daughter (F1.5), in four of
her brothers (F1.2, F1.3, F1.4, and F1.10) and one of her
two sisters (F1.7), as well as in the daughters (F1.6, F1.9)
of two of the affected brothers. MLPA assays did not
reveal any copy number differences in patients F1.1, F1.4
and F1.10.
At age 52 years, the first brother (F1.3) was referred
for examination to exclude malignant monoclonal gam-
mopathy IgG-kappa. At age 40 years, he underwent
vertebral fixation surgery because of severe back pain.
He reported acroparesthesia, heat intolerance, and hypo-
hidrosis since childhood, as well as shortness of breath
and inability to perform any physical activity. This
patient was hemizygous for the CIH.
The second brother (F1.10), hemizygous for the CIH,
was 49 years old. His main symptoms were related to left
ventricular hypertrophy and valvular aortic stenosis
associated with severe acral pain that demanded con-
tinuous intake of analgesic drugs.
The third brother (F1.13) did not accept to be a part
of the study and the fourth brother was deceased.
The fifth brother (F1.4) was referred for hearing loss
and mild acroparesthesia at 41 years of age. Renal
involvement was characterised by microalbuminuria
(34 mg/24 h) and glycolipid deposits in renal tubules
and glomeruli (Fig. 2). It is important to note that this
patient did not use chloroquine or amiodarone-like
drugs. His 7-year-old daughter (F1.6) had microalbumi-
nuria (29 mg/24 h), and was heterozygous for the CIH.
The sixth brother (F1.2) was 39 years old, hemizygous
for the CIH, and was referred for acroparesthesias,
bilateral hearing loss, heat intolerance and hypohidrosis,
but no cardiac abnormalities were observed.
One sister (F1.7) was 37 years old and a carrier of the
CIH. She had a previous history of tachyarrhythmias, and
since childhood she had acroparesthesias, hypohidrosis
and heat intolerance. Her mother (F1.8) presented no
clinical manifestations.
α-Gal A activity in plasma, leukocytes and fibroblasts
Enzymatic activity was measured in plasma, lysed leuko-
cytes and fibroblasts from CIH carriers and normal
healthy controls. The individual values from leukocytes
and plasma are presented in Table 1. The mean value of
lysed leukocyte activity in the control group (n = 27) was
(mean ± SD) 58.1 ± 26.6 nmol/mg protein/h. Signifi-
cantly lower levels were found in the CIH group (n = 8),
46.25 ± 9.66 nmol/mg protein/h (Fig. 3a; p ≤ 0.05).
The mean value of plasma activity in the control
group (n = 33) was (mean ± SD) 20.8 ± 12.5 nmol/mL/h,
whereas the mean value for the CIH group (n = 9) was
19.5 ± 10.3 nmol/mL/h. There was no significant differ-
ence between the plasma activity in control and CIH
group (Fig. 3a). Enzymatic activity was also measured in
cultured skin fibroblasts from controls and from patients
F1.1, F1.3, F1.4 and F1.10. The activity measurements in
the patients’ fibroblasts were not significantly different to
controls, although there was a trend for reduction in pa-
tient F1.10 and fibroblasts from patient F1.3 had
significantly higher levels of α-Gal A (Fig. 3b).
In vitro model of lysosomal storage disease
In order to accurately determine galactosphingolipid
levels, we first used wild-type fibroblasts to establish a
model of lysosomal storage dysregulation. Fibroblasts
were treated or not with TNFα (16 h) to activate a
proinflammatory response, followed by a medium
change without TNFα, and culturing was then continued
Fig. 2 Cytoplasmic vacuolation observed in a podocyte by light microscopy with a Masson’s trichrome and b Haematoxylin and eosin staining.
c Myelin-like structures in a podocyte, with concentric lamellated ultra-structural appearance. (Electron Microscopy). d Focal areas of podocyte
effacement; amorphous myelin-like structures are visible in glomerular parietal epithelial cells and in endothelial cells (Electron Microscopy).
e Myelin-like structures parallel with zebra-like body appearance (Electron Microscopy)
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Table 1 Clinical manifestations; α-Gal A activity in plasma and leukocytes, galactosphignolipid concentrations and GLA mRNA expression
ID SEX Age Variants Clinical Manifestations galactosphingolipids galactosphingolipids α-Gal A α-Gal A mRNA mRNA
CIH Leukocytes Fibroblasts Leukocytes Plasma GLA GLA-M
(nmol/mg protein) (nmol/mg protein) (nmol/mg protein/h) (nmol/mL/h) RQ RQ
F1.1 f 43 Het Ischemic heart disease, Gastro- intestinal,
Fine fiber alterations
0.62 0.83 63 23 0.48* 0.85
F1.2 m 39 Hemi Acroparesthesias, Heat intolerance,
Hypohidrosis, Hearing loss
0.13 N/A 57 19 0.41 5.47
F1.3 m 53 Hemi Acroparesthesias, Heat intolerance,
Hypohidrosis
0.11 0.80 38 14 0.36* 0.84
F1.4 m 41 Hemi Hearing loss, Microalbuminuria,
Renal deposits
0.11 1.12 37 15 0.88 2.56
F1.5 f 20 Het N/A 0.13 N/A 42 37 N/A N/A
F1.6 f 7 Het Microalbuminuria N/A N/A N/A 9 N/A N/A
F1.7 f 37 Het Acropaesthesias, Microalbumminuria,
Hypohidrosis, Tachyarrhythmias
0.06 N/A 43 15 1.06 1.51
F1.8 f 72 Het N/A 0.27 N/A 51 35 1.12 0.90
F1.10 m 49 Hemi Left Ventricular Hypertrophy 1.93 0.93 39 9 0.02** 117.76**
CIH = c.-10C > T [rs2071225], c.369 + 990C > A [rs1023431], c.370-81_370-77delCAGCC [rs5903184], c.640-16A > G [rs2071397], c.1000-22C > T [rs2071228]. The mean ± SD normal concentration of leukocytes
galactosphingolipids is (n = 17) 0.33 ± 0.3 (nmol/mg protein). The mean ± SD normal concentration of fibroblasts galactosphingolipids is (n = 5) 0.63 ± 0.12 (nmol/mg protein). The normal mean ± SD of α-Gal A leukocyte
activity in our assay is (n = 27) 58.1 ± 26.6 (nmol/mg protein/hour) and normal mean ± SD of α-Gal A plasma activity is (n = 33) 20.8 ± 22.03 (nmol/mL/ hour). * = p < 0.05, ** = p < 0.001. N/A = Not applicable
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for a further 8 h. Accumulation of galactosphingolipids
was measured by galactose oxidase assay at 16 h and
24 h has described. TNFα treatment resulted in an in-
crease in galactosphingolipids in wild-type fibroblasts
compared with control samples (without TNFα treat-
ment) (Fig. 4a). Notably, this increase was accentuated by
co-treatment of fibroblasts with TNFα and DGJ, used at a
concentration which inhibits endogenous α-Gal A activity
[19] (Fig. 4a). Moreover, addition of recombinant agalsi-
dase alfa significantly decreased the level of endogenous
galactosphingolipids in TNFα-treated fibroblasts with re-
spect to control cells (Fig. 4a). To corroborate these re-
sults, immunofluorescence microscopy was performed to
evaluate the presence of Gb3 (CD77) using an antibody to
CD77 (Fig. 4b). In good agreement with the biochemical
assay, immunofluorescence staining of fibroblasts exposed
to TNFα demonstrated an increase in CD77, which co-
localized with the lysosomal membrane marker LAMP1.
Additionally, Gb3 signal intensity was increased upon
exposure of fibroblasts to TNFα and DGJ (Fig. 4b). Super-
imposition of CD77/LAMP1 images revealed a significant
degree of overlap (Fig. 4b). As anticipated, agalsidase alfa
treatment reduced Gb3 accumulation as demonstrated by
decreased CD77 fluorescence, without affecting LAMP1
staining (Fig. 4b). Quantification of overlapped pixels of
confocal images revealed that TNFα treatment resulted in
a 50 fold increase in CD77 staining in fibroblasts, which
further increased to 150 fold after 24 h (Fig. 4c). Co-
treatment with DGJ further increased CD77 staining
and this was dramatically reduced upon exposure to
agalsidase alfa (Fig. 4c). A similar analysis was per-
formed with an antibody to lactosylceramide (CD17).
α-Gal A catalyzes the hydrolysis of Gb3 to lactosylceramide
and α-galactose. Lactosylceramide acumulation was de-
creased upon exposure of fibroblasts to TNFα and DGJ.
Agalsidase alfa treatment increased lactosylceramide accu-
mulation as demonstrated by increased CD17 fluorescence,
corroborating the CD77 results (Fig. 4c). Collectively, these
results show that galactosphingolipids can be precisely
measured in cell cultures using this assay and immunocyto-
chemistry is a useful technique to assess lipid storage.
Quantification of galactosphingolipids in leukocytes and
human fibroblasts
Quantification of galactosphingolipids was performed in
leukocytes and fibroblasts from CIH carriers and controls.
The individual values of leukocyte galactosphingolipids
are presented in Table 1. The mean value for the control
group (n = 17) was (mean ± SD) 0.33 ± 0.30 nmol/mg
protein and in the CIH group (n = 8) 0.42 ± 0.63 nmol/mg
protein. Galactosphingolipids were also measured in
cultured fibroblasts from CIH patients. After 5 days of
quiescence, in all cases galactosphingolipid levels in
patient fibroblasts were greater than in equivalent control
cell lines, which was significant for patients F1.1, F1.4 and
F1.10 (Fig. 5a). Interestingly, in patients F1.3 and F1.4,
leukocyte levels were lower than controls, whereas in
equivalent fibroblasts the levels were higher. The origin of
these differences may reflect distinct GLA expression
states of different cells. Ferreira et al., suggest that the
GLA 5’UTR polymorphysms are a possible modulators of
GLA expression varying among different cell types [24].
Atypical FD variants are often not associated with
increased lyso-Gb3 levels, although biopsies of affected
organs revealed lamellar inclusion bodies characteristic for
FD [25]. Consistent with the increase in galactosphin-
golipids, immunostaining of fibroblasts from patient
F1.4 and F1.10 revealed elevated levels of Gb3, which
were further increased after exposure to TNFα (Fig. 5b).
Additionally, immunofluorescence revealed that galacto-
lipids were mostly confined to cytosolic and membrane
compartments (Fig. 5b). Quantification of CD77/LAMP1
lysosomal co-localization revealed an increase in
CD77 staining in fibroblasts from patients F1.4 and
F1.10, which was significant for patient F1.10 relative
to control values (Fig. 5c).
cDNA analysis
No sequence changes were discovered after seq-
uencing nested PCR products of the two GLA
Fig. 3 α-Gal enzyme activity. a Enzymatic activity in lysed leukocytes
(nmol/mg protein/hour) and plasma (nmol/mL/hour), represented as
mean ± SEM. b Enzymatic activity in lysed fibroblasts (nmol/mg
protein/hour) represented as mean ± SEM, n = 3 *p≤ 0.05
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amplicons in comparison with the reference sequence
(data not shown).
Small RNA cloning
Sequencing of the 3′ region of intron 6 insert in all
CIH carriers revealed the presence of one cDNA frag-
ment formed by a 49-bp portion of intron 6 and exon 7
cloned only in patient F1.4. The genomic coordinates
of this exon 7 extension are: ChrX(GRCh38):
g.101398050-g. 101397803 :-1.
Quantitative PCR of the GLA transcripts
Relative quantification (RQ) of wild-type (wt) GLA and
GLA-M mRNA (3′ region of intron 6 cloned fragment)
from all carriers and controls (n = 8; 50 % females) was
performed by real-time PCR and the GLA/GLA-M ex-
pression profiles were compared between control group
and carriers. Reduced wt GLA expression was found in
all hemizygous carriers and in the heterozygous proband
F1.1, and was significant in carriers F1.3, F1.10 and F1.1
(Table 1). The relative expression of GLA-M was
increased in carriers F1.2, F1.4 and F1.7, and signifi-
cantly in patient F1.10 compared with controls (Table 1).
The heterozygous group for CIH presented higher RQ
values for GLA wt expression in comparison with the
hemizygous group (0.89 vs 0.41).
Electrophoretic mobility shift assay (EMSA)
To investigate whether the C > T change in the GLA
gene promoter variant c.-10C > T impacted the binding
capacity of possible transcription factors, EMSA was
performed with specific primers for each variant. The
results demonstrated marked differences in the affinity
of nuclear proteins between the two alleles, with allele C
having a greater ability to bind nuclear proteins (Fig. 6a).
To confirm this difference, we performed a competitive
BA
C
D
Fig. 4 Model of FD substrate accumulation in vitro. a Galactosphingolipid variation rate in wild-type fibroblasts under different conditions.
Galactosphingolipids concentration was measured as described (n = 3) and changes in galactosphingolipids levels are represented. b Representative
images of in vitro FD model. Control fibroblasts were stained with CD77 (Gb3), green and LAMP1, red. CD77 and LAMP1 merged appear
as orange/yellow. Nuclei were stained with DAPI, blue. b.1) Control 24 h; b.2) Control + TNFα 24 h; b.3) Control + TNFα 24 h + DGJ;
b.4) Control + TNFα 24 h + agalsidase alfa. c Quantification of CD77/LAMP1 (orange/yellow) fluorescence rate (n = 3). d Quantification of
CD17/LAMP1 (orange/yellow) fluorescence rate (n = 3)
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binding EMSA using increasing amounts of an unlabelled
oligonucleotide corresponding to the T allele. The
results indicated that the T allele was more easily
displaced from the protein-DNA complex (0.003 vs
0.001) (Fig. 6b). Therefore, the C > T substitution re-
sulted in decreased protein binding capacity of the frag-
ment. In an attempt to identify the transcription factors
present in the complex, we scanned sequences sur-
rounding the SNP c.-10C > T with MatInspector (Geno-
matix) [26]. The results of this analysis indicated that
the mutation could affect the binding sites for small
nuclear RNA (snRNA)-activating protein complex
(SNAP-C), doublesex/mab-3 related (DMRT), and X
box-binding factors.
Splice-site score (SSS)
We analysed the variants of the CIH using SSPNN soft-
ware. Changes in GLA splicing with CIH were observed
only in c.370-81_370-77delCAGCC and c.640-16A > G
variants. The c.370-81_370-77delCAGCC variant re-
sulted in the disappearance of a possible acceptor site
in IVS2-78, with a SSS of 0.80. The SSS for a normal
acceptor site in intron 4 (IVS4-1) was raised from
0.58 to 0.62 with the c.640-16A > G variant. Although
the SSS were minimal, the results indicated that the
co-segregation of CIH variants may cause an abnor-
mal splice pattern.
Discussion
Detection of mutations in the GLA gene is essential to
support clinical diagnosis of FD. Mutations in intronic re-
gions can alter the GLA gene expression pattern in a man-
ner related to different disease phenotypes and clinical
manifestations [4, 5]. Intronic GLA variants often remain
unidentified because these regions are not routinely evalu-
ated by gene sequencing; consequently, the prevalence of
FD may be underestimated [27, 28].
A
C
B
Fig. 5 Accumulation of galactosphingolipids in fibroblast lysates. a Biochemical quantification after 5 days of culture represented as mean ± SEM.
(n = 3) *p≤ 0.05 **p≤ 0.001. b Quantification of Gb3 (CD77) confocal images represented as mean ± SD (n = 3) b.1) patient F1.10.*p≤ 0.05; (+)TNFα vs.
(−)TNFα and #p ≤ 0.05; Control vs. F1.10., b.2) Patient F1.4. c Immunocytochemistry of CD77 expression in fibroblasts from c.1) control, c.2)
patient F1.4 and c.3) patient F1.10 after 16 h TNFα activation. Nuclei were stained with DAPI, blue
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In the present study, we sequenced the entire GLA gene
from genomic DNA of the family members and we used
MLPA in an attempt to find alterations that could explain
the FD-like characteristics observed. We identified a
complex haplotype consisting of five intronic variants
(c.-10C >T, c.369 + 990C >A, c.370-81_370-77delCAGCC,
c.640-16A >G, c.1000-22C >T). In one study, 12 % of 740
subjects with clinically suspected FD showed polymor-
phisms in the GLA promoter region; of these, 99 % had
simultaneous polymorphisms throughout the gene, and
CIH formed by four of five variants observed in our study
occurred in 9 % of these cases [11]. In a second study, Ferri
and colleagues [13] identified five GLA haplotypes in
non-coding regions in 67 female probands with FD
manifestations. The most frequent of these was the CIH
formed by four variants (13.4 %). Previous reports have
found c.-10C > T, c.370-81_370-77delCAGCC, c.640-
16A > G and c.1000-22C > T variants to be associated
with different clinical manifestations including mild
renal, neurological [10] and cardiac disorders [12]. It is
important to know that depending on the sequencing
design, these haplotypes might be the same type. We
found FD-like symptoms (renal, cardiac and neurological
involvement) associated with the family in our study
(Table 1). In accordance with our results Apeland et al.,
described two unrelated families, one of them carrier of
c.640-16A > G and c.1000-22C > T intronic variants,
presenting a cardiomyopathy mimicking FD with nor-
mal enzymatic activity values and renal and cardiac
deposits without accumulation of glycolipids in urine
or plasma. In two patients, a 100-fold increase in Gb3
was observed in cardiac biopsies. Exon sequencing
failed to detect heterozygosity in potential candidate
genes [29].
We examined the c.-10C > T variant located in the
GLA gene promoter region, which may be co-
dominantly associated with a relatively decreased GLA
expression at the level of transcription and/or translation
[30]. By EMSA, we found that the T allele reduced the
affinity of the nuclear protein binding site. A computer
analysis using MatInspector showed that this region is a
possible binding site for three families of transcription
factors: SNAP-C, X box-binding factors (XBBF) and
DMRT. SNAP-C binds to Oct-1 and TATA binding
proteins (TBP), which are activators of snRNA and RNA
polymerases, respectively [31]. X box-Protein 1 (XBP1)
becomes initiated during the endoplasmic reticulum
(ER) stress response [32]. In humans, the DMRT gene
family encodes transcription factors that are related to
the Drosophila double sex proteins [33]. Unfortunately,
no tested antibodies are currently available to perform a
supershift assay.
The c.-10 C >T variant is situated in a CpG island region
(http://www.urogene.org/methprimer/). DNA methylation
Fig. 6 EMSA analysis. a EMSA carried out with probes containing the C or T allele for the IVSO-10C > T variant in the GLA gene promoter. b The
inverse of band densities from the EMSA plotted against the excess of cold allele T oligonucleotides, showing that allele T (slope = 0.003) was more
easily displaced from the complex than allele C (slope = 0.001)
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is a well-recognized epigenetic modifier in the control of
gene expression. This reversible DNA modification takes
place almost exclusively at cytosine residues that are associ-
ated with guanosine in CpG doublets, and mediates con-
trol of transcription through chromatin remodelling.
This modification is widely implicated in various
biological processes including X-inactivation, the regu-
lation of tissue- and development-specific gene expres-
sion, foreign DNA inactivation and genomic imprinting
[34]. FD symptoms exhibited by females carrying the T
allele could partially depend on the methylation state of
the C allele. Indeed, Bono and co-workers [11] reported a
relationship between FD symptoms and polymorphisms in
the promoter region. Future studies on the methylation
states of the promoter region may provide more clues on
these epigenetic effects in relation to phenotype.
We found low levels of wild-type transcript in some
patients in agreement with previous reports [28, 35].
GLA-M transcript levels (3′ region of the intron 6
cloned fragment) were also altered with respect to their
controls in most cases. The index case of this family
(F1.1), a female heterozygous for CIH, presented signifi-
cantly lower levels of wild-type transcript, whereas GLA-
M expression was slightly reduced but not significantly
different to control. Although she presented a cardiac
phenotype, her leukocyte and plasma enzyme activities
were not decreased. Higher residual activity is often found
in atypical male patients who do not show the classic
phenotype and have later onset of symptoms [36, 37],
including cardiac [35] and renal variants [38]. It is possible
that GLA expression in other tissues may be different. The
ratio of the alternatively spliced transcript produced by
another intronic variant, IVS4 + 919G > A mutation, to
total α-Gal A mRNA, is higher in human muscle and lung
tissues [27]. In the case of this studied family, the CIH
only produced an altered GLA expression profile, presum-
ably resulting in a late-onset FD-like phenotype. The
differences observed in the qPCR assay may coincide with
the SSS data variations for c.370-81_370-77delCAGCC
and c.640-16A >G variants, the EMSA assay results for c.-
10 C > T and also with the cDNA cloned fragment formed
by a 49-bp segment of 3′ intron 6 and exon 7 in patient
F1.4. However, PCR and sequencing did not reveal any
products of splicing variants due to c.370-81_370-77del-
CAGCC or c.640-16A >G. It is possible that these tran-
scripts are degraded by nonsense-mediated mRNA decay.
In accord with the EMSA results, the expression levels of
heterozygous CIH patients were approximately 50 %
higher than in hemizygous carriers. Enzymatic activity was
measured in plasma, lysed leukocytes and fibroblasts from
CIH carriers and normal healthy controls. The mean value
of lysed leukocyte activity in the CIH group was signifi-
cantly lower (~20 %) but there was no significant
difference between the plasma and fibroblast activity
in control and CIH group. The expression is reduced
in leukocytes reducing the enzyme activity but no the
enzyme activity in other tissues like plasma support-
ing previous studies [30]. This effect may contribute
to the glycolipid alteration and therefore may develop
the clinical findings.
The levels of storage products in urine and plasma are
elevated in most, but not all, FD patients. The demon-
stration of increased storage product levels is very useful
in making a diagnosis in many cases and also for treat-
ment monitoring. The predominant storage product in
FD is Gb3, but other storage products such as Ga2 or
lyso- Gb3 may also accumulate. Consequently, significant
differences in the Gb3 and Ga2 isoform profiles in urinary
sediment were found amongst young, adult and atypical
hemizygotes and heterozygotes using a combination of
MALDI-TOF MS and tandem MS [39]. Additionally,
increased sphingolipid storage in skin fibroblasts from
patients has been described previously [40]. Therefore, we
used an enzymatic fluorometric technique to quantify all
galactosphingolipids in samples obtained from controls
and CIH carriers in lysed leukocytes and skin fibroblasts.
Galactose is a component of the headgroup of many
glycolipids. Galactose oxidase specifically oxidizes the C-6
hydroxymethyl group of free galactose as well as all galac-
tosyl derivatives, such as Gb3, lyso- Gb3 and Ga2, carrying
a galactose residue in the terminal position. Bile acids, for
example sodium taurocholate, do not alter the kinetics of
galactose oxidase [41]. The enzymatic method to detect
urinary Gb3, showed a good recovery and comparability
with a previously validated HPLC method [42]. Import-
antly, we validated this assay using a synthetic model of
lysosomal storage in fibroblasts activated with TNFα and
corroborated these findings with confocal microscopy
quantification of CD77 (Gb3)/CD17(Lactosylceramide)/
LAMP1. Confocal microscopy revealed that galactolipids
were mostly confined to cytosolic and membrane com-
partments (Fig. 5b) in concordance with several studies
that demonstrated that Gb3 in FD is not only present in
lysosomes, but rather widely distributed in other cellular
structures [43]. In vitro studies in skin fibroblasts showed
that CIH carriers accumulated galactosphingolipids
significantly after 5 days culture, in the range between 30
and 80 % in comparison with control samples. Fibroblasts
from a male patient (F1.4) with a renal phenotype
and glycolipid deposits demonstrated by renal biopsy,
accumulated approximately 50 % more substrate com-
pared with the F1.1 patient, a heterozygous female
with a cardiac phenotype. In concordance with our
results is important to remark that Namdar et al.
demonstrated that vasculopathy in FD is directly
caused by intracellular Gb3 accumulation while defi-
ciency of GLA alone does not cause any deregulation
of key vasoactive mediators [44].
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Most of the carriers had high in vitro residual enzyme
activity in plasma, leukocytes and cultured fibroblasts;
however, CIH carriers had significant galactosphingolipid
accumulation in fibroblasts in comparison with controls.
Presumably, because the enzyme structure is not altered,
only the GLA structural regulatory mechanism was affected
by inheritance of the CIH, leading to GLA activation-
dependent accumulation of substrates, influenced perhaps
by environmental factors such as the proinflammatory state
of the patient.
Conclusions
CIH carriers showed a wide variation in residual enzym-
atic activities in leukocytes, plasma, and fibroblasts, but
generally activity was normal. In contrast, galactosphingo-
lipid accumulation was in the main significantly greater in
fibroblasts compared with controls. Position −10 in the
GLA promoter is a putative nuclear protein binding site
situated in the CpG island region, acting as a gene regula-
tory zone. The inheritance of the co-segregated CIH
variants alters the GLA expression pattern, producing a
tissue glycolipid storage disorder.
The genetic analysis of the entire GLA gene sequence
and MLPA, the study of GLA expression and glycolipid
quantification in relation to FD clinical manifestations can
be extremely helpful as tools for FD-related diagnosis.
Further studies are needed to elucidate how the
inheritance of complex intronic haplotypes are impli-
cated in the GLA regulatory mechanisms and therefore,
the glycolipid metabolism alteration.
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